OncoMatch/Clinical Trials/NCT07116486
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
Is NCT07116486 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for hepatocellular carcinoma.
To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07116486 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages